Cathepsin K, a cysteine protease of the papain family, was identified by se
quencing complementary DNA libraries derived from osteoclasts. Cathepsin K
can cleave bone proteins such as Type I collagen, osteopontin, and osteonec
tin. The localization and maturation of cathepsin K in activated osteoclast
s have been characterized. Furthermore, mutation of the gene expressing cat
hepsin K in humans results in pycnodysostosis, an autosomal recessive condi
tion, resulting in osteoprosis and increased bone fragility. Knockout of ca
thepsin K in the mouse also results in retarded bone matrix degradation and
osteopetrosis. Together, these data demonstrate that inhibition of catheps
in K should result in a dimunition of osteoclast-mediated bone resorption.
Several novel classes of cathepsin K inhibitors have been designed from X-r
ay co-crystal structures of peptide aldehydes bound to papain. The converge
nce of the design of novel inhibitors and the discovery of cathepsin K has
created opportunities to further understand bone and cartilage biology as w
ell as provide new therapeutic agents for the treatment of disease states i
n man such as osteoporosis.